FibroBiologics, Inc. filings document the regulatory record of a clinical-stage biotechnology issuer developing fibroblast-based therapies. Recent disclosures cover registered equity financing through an at-the-market common stock program, shelf registration mechanics, common stock and warrant-related capital structure matters, and corporate uses of proceeds for working capital and general corporate purposes.
The company’s SEC filings also record governance and public-company administration, including annual meeting proxy proposals, director election and auditor ratification matters, stock-plan option grants to executive officers, Nasdaq continued-listing compliance, amendments to stockholder-meeting quorum provisions, and material agreements affecting its operating footprint.
FibroBiologics, Inc. reported $1,200,000 in securities sold under a Rule 506(b) offering, with $0 remaining to be sold. The amount includes a convertible debenture with $1,200,000 principal and 125,000 restricted shares. The debenture is convertible only following an event of default, at a fixed conversion rate of $0.78 per share. The first sale occurred October 7, 2026. The company intends to use net proceeds for working capital and general corporate purposes.
FibroBiologics, Inc. (FBLG) closed a private placement with Peak One Opportunity Fund, L.P. on October 8, 2026, issuing a $1.2 million principal convertible debenture for a $1.02 million purchase price, reflecting a 15% original issue discount, and 125,000 restricted Commitment Shares to Peak One and its designee.
The debenture matures October 8, 2027, bears 0% annual interest, and is convertible at $0.78 per share only after an Event of Default. Payments are $1,080,000 on April 8, 2027, $60,000 on July 8, 2027, and $60,000 or the remaining balance, if higher, at maturity. Following default, the holder may raise interest to the lesser of 18% or the legal maximum and accelerate the full indebtedness in an amount equal to 120% of outstanding principal and accrued and unpaid interest. Issuances under the SPA and debenture are capped at 1,671,094 shares absent stockholder approval, with a 4.99% beneficial-ownership limit. At the holder's sole discretion, if aggregate cash proceeds exceed $1.5 million, the company agreed to use 50% of those proceeds to repay the debenture and, subject to limited exceptions, not enter a Variable Rate Transaction while it remains outstanding.
FibroBiologics, Inc. (FBLG) reports that stockholders approved, for purposes of Nasdaq Listing Rule 5635(d), the potential issuance of up to 8,163,266 shares of common stock upon exercise of warrants issued under a June 25, 2026 Securities Purchase Agreement and up to 285,714 shares upon exercise of additional warrants issued under an engagement letter with H.C. Wainwright & Co., LLC. At the September 17, 2026 Special Meeting, 3,431,761 votes were represented out of 8,283,193 entitled votes, and the proposal passed with 3,153,098 for, 258,217 against, and 20,446 abstentions.
The company also closed a $0.5 million private placement on September 15, 2026 with Chief Scientific Officer Hamid Khoja, Ph.D., involving 298,508 shares of common stock and accompanying warrants to purchase up to 298,508 shares. Each share-and-warrant unit was sold at $1.675, reflecting a common share value of $1.55 plus $0.125 per warrant. The warrants are immediately exercisable at $1.55 per share and expire five years from issuance, with net proceeds intended for general corporate purposes and working capital.
FibroBiologics, Inc. (FBLG) entered into a private placement with its Chief Scientific Officer, Hamid Khoja, on September 15, 2026, under which he purchased 298,508 shares of common stock together with warrants to purchase up to 298,508 additional shares. The securities were sold at an offering price of $1.675 per share and accompanying warrant, for gross proceeds of approximately $0.5 million. The warrants are exercisable at any time at an exercise price of $1.55 per share and expire five years from issuance, with standard anti-dilution adjustments. Following this transaction, Dr. Khoja beneficially owns 630,009 shares of FibroBiologics common stock (including common shares, warrant shares and vested options), representing about 7.5% of the outstanding common stock.
FibroBiologics, Inc. (FBLG) reported that Chief Scientific Officer Hamid Khoja acquired 298,508 shares of common stock on September 15, 2026 at $1.675 per share in a private placement, together with warrants to purchase up to 298,508 additional shares at an exercise price of $1.55 per share, exercisable until September 15, 2031. Following these awards, he holds 301,571 shares of common stock directly, along with 298,508 warrants.
FibroBiologics, Inc. (FBLG), a Delaware biotechnology company, filed a Form D for a new exempt private offering under Rule 506(b) of Regulation D. The company reports that it has sold $500,001 of securities in this offering, with no remaining amount available to be sold.
The securities consist of 298,508 shares of common stock and accompanying warrants exercisable at $1.55 per share for up to an additional 298,508 shares of common stock. The issuer states it intends to use the net proceeds for working capital and general corporate purposes, and reports no finders’ fees paid.